Pittsburgh Brain Surgeon Gets Life for Poisoning Wife With Cyanide-Spiked Diet Drink
(Reuters) — A University of Pittsburgh neurological surgery professor was sentenced to life in prison on Wednesday after his first-degree murder conviction in the poisoning death of his wife, who was also a doctor.
Dr. Robert Ferrante, 66, appeared before Judge Jeffrey Manning at the Allegheny County Courthouse in Pennsylvania but did not speak on his own behalf, according to one of his lawyers, Wendy Williams.
His lawyer’s request for a new trial was not granted, but could be considered as a post-sentencing motion once supplementary material was added.
“All the evidence against him was circumstantial,” Williams said. “It’s just sad,” she added.
Ferrante was accused of poisoning his wife, Dr. Autumn Klein, 41, by lacing her dietary supplement drink with cyanide ordered through his research lab at the university.
A Pittsburgh jury found him guilty of first-degree murder in November, making him subject to a mandatory minimum sentence of life in prison without the possibility of parole.
Shortly after his conviction, a second woman, who like Klein was an employee of the University of Pittsburgh Medical Center, was found dead of cyanide poisoning. The Allegheny County Medical Examiner recently ruled that the death of Nicole Kotchey, 35, was a suicide.
Before the sentencing, Prosecutor Lisa Pellegrini read victim impact statements on behalf of Autumn Klein’s family, including her parents.
Her mother, Lois Klein, who is caring for Ferrante’s daughter, Cianna, 8, wrote: “This child now, is not only without a mother – she is also without a father.”
During the trial, Pellegrini told jurors that the couple’s marriage was troubled and that Klein may have been about to leave her husband.
Ferrante “wanted her dead, dead, dead” and felt that if he could not have Klein, then “no one will,” Pellegrini said in her closing arguments.
Ferrante’s other lawyer, William Difenderfer, argued that Klein did not die of cyanide poisoning and contended Ferrante ordered the substance for clinical research purposes.
A message from our CEO & publisher Rachel Fishman Feddersen
I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.
At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and polarized discourse..
Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.
— Rachel Fishman Feddersen, Publisher and CEO